ChemoMetec AS (OCSE:CHEMM) Owner Earnings per Share (TTM): 9.22 (As of Jun. 2025) — 90% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:CHEMM ChemoMetec AS OCSE:CHEMM
89 GF Score
Price kr475.00
GF Value kr518.17
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is ChemoMetec AS Owner Earnings per Share (TTM)?

ChemoMetec AS OCSE:CHEMM +1.84% 89 Owner Earnings per Share (TTM) is 9.22 as of Jun. 2025, which is 90% below its 10-year median of 94.06. GuruFocus rates OCSE:CHEMM with a GF Score™ of 89/100 and a GF Value™ of kr518.17 (Fairly Valued). The stock has 2 warning signs investors should review. Among 311 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 70.42% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ChemoMetec AS's Owner Earnings per Share (TTM) ended in Jun. 2025 was kr9.22. It's Price-to-Owner-Earnings ratio for today is 51.52.


The historical rank and industry rank for ChemoMetec AS's Owner Earnings per Share (TTM) or its related term are showing as below:

OCSE:CHEMM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 31.44   Med: 94.06   Max: 274.22
Current: 46.62


During the past 13 years, the highest Price-to-Owner-Earnings ratio of ChemoMetec AS was 274.22. The lowest was 31.44. And the median was 94.06.


OCSE:CHEMM's Price-to-Owner-Earnings is ranked worse than
70.42% of 311 companies
in the Medical Devices & Instruments industry
Industry Median: 27.61 vs OCSE:CHEMM: 46.62

ChemoMetec AS's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was kr5.40. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr10.17. It's PE Ratio (TTM) ratio for today is 46.71.

ChemoMetec AS's EPS without NRI for the six months ended in Dec. 2025 was kr5.40. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was kr10.17. It's PE Ratio without NRI ratio for today is 46.71.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


ChemoMetec AS Owner Earnings per Share (TTM) Related Terms


ChemoMetec AS Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Owner Earnings per Share (TTM) Chart

ChemoMetec AS Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.84 8.34 7.79 6.40 9.22

ChemoMetec AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.40 0.00 9.22 0.00

OCSE:CHEMM vs ABT, SYK, MDT: Owner Earnings per Share (TTM) Comparison

For the Medical Devices subindustry, ChemoMetec AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoMetec AS Price-to-Owner-Earnings vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ChemoMetec AS's Price-to-Owner-Earnings falls into.


OCSE:CHEMM
89GF Score
ChemoMetec AS OCSE:CHEMM
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ChemoMetec AS Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

ChemoMetec AS's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 186.4
Depreciation, Depletion and Amortization 21.5
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 34.1
Change In Working Capital -13.4
Shares Outstanding (Diluted Average) 17.4

1. Start with "Net Income" from income statement. ChemoMetec AS's Net Income for the trailing twelve months (TTM) ended in Jun. 2025 was kr186.4 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. ChemoMetec AS's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2025 was kr21.5 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. ChemoMetec AS's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2025 was kr0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = kr34.1 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

ChemoMetec AS's 5-Year Average Maintenance Capital Expenditure = kr34.1 Mil

5. "Change In Working Capital" is from cashflow statement. ChemoMetec AS's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2025 was kr-13.4 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. ChemoMetec AS's Shares Outstanding (Diluted Average) for the months ended in Jun. 2025 was 17.402 Mil.

ChemoMetec AS's Onwer Earnings Per Share for Jun. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 186.405 +21.531+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-34.0684+-13.363)/17.402
=9.22

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=475.00/9.22
=51.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 9.22 mean?
ChemoMetec AS (OCSE:CHEMM) has a Owner Earnings per Share (TTM) of 9.22 as of Jun. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ChemoMetec AS. This is 90% below median its historical median of 94.06. Over the past decade, ChemoMetec AS's Owner Earnings per Share (TTM) has ranged from 31.44 to 274.22. According to the industry distribution chart, ChemoMetec AS ranks #219 out of 311 companies in the Medical Devices & Instruments industry, placing it in the top 70.4%.
Is ChemoMetec AS's Owner Earnings per Share (TTM) too high?
ChemoMetec AS's current Owner Earnings per Share (TTM) of 9.22 is 90% below median its 10-year median of 94.06. Over the past 10 years, this metric has ranged from a low of 31.44 to a high of 274.22. The Medical Devices & Instruments industry median Owner Earnings per Share (TTM) is 27.61. ChemoMetec AS's value of 9.22 is 66.6% below this industry median. Based on the distribution chart, ChemoMetec AS ranks #219 out of 311 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Owner Earnings per Share (TTM) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #219 out of 311 companies for Owner Earnings per Share (TTM). This places ChemoMetec AS in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 27.61. ChemoMetec AS's value of 9.22 is 66.6% below this benchmark. Historically, ChemoMetec AS's own Owner Earnings per Share (TTM) has ranged from 31.44 to 274.22 over the past decade. While the company's 10-year median is 94.06 vs. the industry median of 27.61, ChemoMetec AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Devices & Instruments company?
The median Owner Earnings per Share (TTM) among Medical Devices & Instruments companies is 27.61, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Owner Earnings per Share (TTM) of 9.22 is 66.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ChemoMetec AS. For the Medical Devices & Instruments industry, the median Owner Earnings per Share (TTM) is 27.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Owner Earnings per Share (TTM) is 9.22, which is 90% below median its own 10-year median of 94.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Fairly Valued. The stock's GF Value™ is kr518.17, compared to a current price of kr475.00 — trading 8.3% below its estimated fair value. The current Owner Earnings per Share (TTM) is 9.22, which is 90% below median its 10-year median of 94.06 and 66.6% below the Medical Devices & Instruments industry median of 27.61. ChemoMetec AS's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Owner Earnings per Share (TTM) is 9.22 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr475.00 is trading 8.3% below its estimated GF Value™ of kr518.17. GuruFocus considers ChemoMetec AS to be Fairly Valued.

Key valuation signals for OCSE:CHEMM:

  • Owner Earnings per Share (TTM): 9.22 (90% below median its 10-year median of 94.06)
  • GF Value™: kr518.17 vs. price of kr475.00 (8.3% below fair value)
  • GF Score™: 89/100 with 2 warning signs
  • Industry Position: 66.6% below the Medical Devices & Instruments median (#219 of 311)

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ChemoMetec AS Business Description

Other Exchanges CHEMMc:UK0DZ0:UKCHY:Germany
Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
89GF Score

Get the complete analysis for OCSE:CHEMM

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr475.00
Price
kr518.17
GF Value